Article

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K (Impact Factor: 10.43). 07/2010; 24(7):1302-9. DOI: 10.1038/leu.2010.113
Source: PubMed

ABSTRACT

In a multi-institutional collaborative project, 1473 patients with myeloproliferative neoplasms (MPN) were screened for isocitrate dehydrogenase 1 (IDH1)/IDH2 mutations: 594 essential thrombocythemia (ET), 421 polycythemia vera (PV), 312 primary myelofibrosis (PMF), 95 post-PV/ET MF and 51 blast-phase MPN. A total of 38 IDH mutations (18 IDH1-R132, 19 IDH2-R140 and 1 IDH2-R172) were detected: 5 (0.8%) ET, 8 (1.9%) PV, 13 (4.2%) PMF, 1 (1%) post-PV/ET MF and 11 (21.6%) blast-phase MPN (P<0.01). Mutant IDH was documented in the presence or absence of JAK2, MPL and TET2 mutations, with similar mutational frequencies. However, IDH-mutated patients were more likely to be nullizygous for JAK2 46/1 haplotype, especially in PMF (P=0.04), and less likely to display complex karyotype, in blast-phase disease (P<0.01). In chronic-phase PMF, JAK2 46/1 haplotype nullizygosity (P<0.01; hazard ratio (HR) 2.9, 95% confidence interval (CI) 1.7-5.2), but not IDH mutational status (P=0.55; HR 1.3, 95% CI 0.5-3.4), had an adverse effect on survival. This was confirmed by multivariable analysis. In contrast, in both blast-phase PMF (P=0.04) and blast-phase MPN (P=0.01), the presence of an IDH mutation predicted worse survival. The current study clarifies disease- and stage-specific IDH mutation incidence and prognostic relevance in MPN and provides additional evidence for the biological effect of distinct JAK2 haplotypes.

Download full-text

Full-text

Available from: Terra Lasho, Aug 07, 2014
  • Source
    • "8/277 (2.9) 26/277 (9.4) ND ND ND ND Pardanani A. et al. [25] 5/200 (2.5) 4/200 (2) ND ND ND ND Tefferi A. et al. [7] 10/1327 (0.8) 16/1327 (1.2 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations of isocitrate dehydrogenase isoform 1 and 2 (IDH1 and IDH2) genes have been identified in glioblastoma and acute myeloid leukemia (AML). However, little is known about the molecular alterations of IDH genes in preleukemic disorders with a propensity to transform to AML. We performed polymerase chain reaction-denaturing high performance liquid chromatography (PCR-DHPLC) followed by direct sequencing to detect IDH mutations in 237 patients with myeloproliferative neoplasms (MPNs; n=108), myelodysplastic syndrome (MDS; n=22), paroxysmal nocturnal hemoglobinuria (PNH; n=41), and aplastic anemia (AA; n=66). No IDH1 R132 and IDH2 R172 mutations were identified in the entire cohort, whereas IDH1 G105G allele was detected in 4/108 MPN (3.70%), 2/22 MDS (9.09%), and 2/41 PNH (4.88%) patients. Three IDH2 R140Q mutations were found in 2/108 MPN (1.85%) and 1/22 MDS (4.54%) patients, while one IDH2 G145G allele was found in 0.92% (1/108) of MPN patients. Overall, our data suggest that IDH mutations are rare in the preleukemic disorders and may not be the major initial step in AML leukemogenesis. Copyright © 2014 Elsevier Inc. All rights reserved.
    Full-text · Article · Nov 2014 · Blood Cells Molecules and Diseases
  • Source
    • "However, despite significant insight into the role of specific mutations, including the JAK2V617F mutation, the precise mechanisms in MPN remain elusive. It is very likely that additional mutations in MPN will be described soon, but practical relevance in terms of either disease prognostication or value as drug targets has so far been limited [42]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the discovery of JAK2V617F tyrosine kinase-activating mutation, several genes have been found mutated in myeloproliferative neoplasms (MPNs). FLT3-ITD, NPM1, and DNMT3A mutations frequently occurred in AML patients and have been found conferred with myeloproliferative neoplasms in mouse model. Therefore, we sought to search for mutations in JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in 129 cases including 120 classic MPN cases and 9 MDS/MPN cases. JAK2V617F mutation was found in 60% of the 120 classic MPNs. However, none of the patients displayed FLT3-ITD and NPM1 mutations; only 2 patients harbored DNMT3A R882 mutation. Further studies including whole-genome sequence will be conducted to investigate the possible involvement of these genes in MPN.
    Full-text · Article · May 2014 · BioMed Research International
  • Source
    • "Хотя в настоящее время мутации гена CALR не включены в диагностические критерии, однако при подозрении на МПЗ в отсутствие мутации JAK2 секвенирование экзона 9 гена CALR может оказаться полезным. При ИП и ЭТ выявляются и другие мутации: TET2, IDH, ASXL1, DNMT3A и др.27282930. Ни одна из них не специфична для классических Ph-негативных МПЗ, а их патогенетическая значимость исследуется. Мутации в гене семьи ТЕТ (TET2) встречаются приблизительно в 15% случаев ПМФ и связаны с возрастом и анемией, но нет никакой корреляции с общей выживаемостью или риском лейкемической трансформации[28]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recommendations for the diagnosis and therapy of Rh-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis, unclassified myeloproliferative disease, postpolycythemia and postthrombocytemic myelofibrosis) are developed by the research group for studies of myeloproliferative diseases at the initiative of the Russian National Hematological Society (Chairman: Prof. V. G. Savchenko, Chief Hematologist and Transfusiologist of the Ministry of Health of Russia, Head, Hematology Research Center). The aim of these recommendations is standardization of the diagnostic and therapeutic approaches in Russia. The methodological approaches are based on the conclusive medicine philosophy and the recommendations of the European Leukemia NET (ELN), National Cancer Control Net (NCCN; USA), International Working Group "Myeloproliferative Neoplasm Research and Treatment" (IWG-MRT), and on the experience gained in Russia on the treatment and follow-up of patients with myeloproliferative diseases. The recommendations are developed by a Multicenter research group for studies of myeloproliferative diseases. Scientists from 10 leading institutions contributed to development of the clinical recommendations.
    Full-text · Article · Jan 2014
Show more